(Reuters) – Keros Therapeutics said on Thursday that it has voluntarily halted usage of its 3.0 milligram (mg) and 4.5 mg doses of its high blood pressure treatment in a mid-stage study based on a safety review.
Shares of the company were down 67.2% at $22.49 in premarket trading.
The company said it had halted dosing after observing adverse events of fluid buildup around the heart in the trial.
Keros said it will work with the U.S. Food and Drug Administration and other relevant regulatory authorities to “address this as quickly as possible.”
The trial was testing the company’s experimental drug cibotercept, in combination with background therapy in patients with pulmonary arterial hypertension-a type of high blood pressure that affects the arteries in the lungs.
(Reporting by Sneha S K; Editing by Abinaya Vijayaraghavan)
Comments